<DOC>
	<DOCNO>NCT00225147</DOCNO>
	<brief_summary>Hereditary angioedema ( `` HAE '' ) genetic disorder characterize sudden recurrent attack local swell ( angioedema ) . These attack often painful disabling , , case , life-threatening . `` HAE '' cause mutation `` C1INH '' gene lead decrease blood level functional `` C1INH '' . This multi-center study design ass safety tolerability , efficacy , pharmacokinetics/pharmacodynamics recombinant human C1 inhibitor ( `` rhC1INH '' ) treatment acute hereditary angioedema attack . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Recombinant Human C1 Inhibitor Treatment Acute Attacks Patients With Hereditary Angioedema</brief_title>
	<detailed_description>A prospectively plan interim analysis perform double-blind data .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Main Clear clinical laboratory diagnosis HAE Plasma level functional C1INH le 50 % normal Acute abdominal , urogenital , peripheral , and/or orofacial/pharyngeal/laryngeal HAE attack Main Acquired angioedema Pregnancy breastfeed Treatment investigational drug within prior 30 day Body weight &gt; 120 kg</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>